Some tips on 1260670-05-0

With the complex challenges of chemical substances, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

It is a common heterocyclic compound, the naphthyridine compound, 3-Bromo-8-chloro-1,7-naphthyridine, cas is 1260670-05-0 its synthesis route is as follows.,1260670-05-0

Step 2 – Synthesis of tert-butyl (R)-(4-(5-((3-bromo-l, 7-naphthyridin-8-yl)amino)-2- fluorophenyl)-2,4, 7, 7-tetramethyl-l, l-dioxido-l,2,5-thiadiazepan-6-ylidene)carbamate To a solution of 3-bromo-8-chloro-l,7-naphthyridine (205 mg, 0.840 mmol) and (R)-tert- butyl (4-(5-amino-2-fluorophenyl)-2,4,7,7-tetramethyl- 1 , 1 -dioxido- 1 ,2,5-thiadiazepan-6- ylidene) carbamate (300 mg, 0.70 mmol) in DMA (3 mL) was added KHMDS (2.45 mL, 2.45 mmol, 1.0 M in THF). The mixture was heated to 50 C and stirred for 2 h. The mixture was cooled and diluted with ethyl acetate. After separation, the organic layer was washed with brine, dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel, eluting with 0-5% MeOH in DCM, to afford the desired product.

With the complex challenges of chemical substances, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

Reference£º
Patent; MERCK SHARP & DOHME CORP.; DAI, Xing; CUMMING, Jared, N.; SCOTT, Jack, D.; LIU, Hong; PALANI, Anandan; WO2015/95104; (2015); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

Share a compound : 1260670-05-0

1260670-05-0 is used more and more widely, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

3-Bromo-8-chloro-1,7-naphthyridine, cas is 1260670-05-0, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

1260670-05-0, [(R)-5-(5-Amino-2-fluoro-phenyl)-5-difluoromethyl-5,6-dihydro-2H-[1 ,4] oxazin-3-yl]-carbamic acid tert-butyl ester (CAS registry 1262859-09-5) (250 mg, 0.696 mmol) and 3-bromo-8- chloro-[1 ,7]naphthyridine [Heteroaryl 1] (186 mg, 0.765 mmol) were dissolved in tert-Butanol (4 ml) in a microwave vial and HCI (0.174 ml of a 4M solution in dioxane) was added. The vial was sealed and heated to 100 C for 1 h. The reaction mixture was cooled to rt and added to a saturated NaHC03 solution (20 ml) and stirred at rt for 10 min.The solution was extracted with DCM (2 x 30 ml). The combined organic layer was washed with NaHC03 solution and brine, treated with MgS04, filtered and to give the desired product. HPLC: RtH9= 0.90 min; ESIMS [M+H]+ = 465.9/467.9(1 Br);1H-NMR (400 MHz, CDCI3): delta 8.90 (s, 1 H), 8.64 (m, 1 H), 8.27 (m, 1 H), 8.08 (d, 1 H), 7.90 (dd, 1 H), 7.10 (dd, 1 H), 6.82 (d, 1 H), 6.34-6.06 (t, 1 H), 4.35 (dd, 1 H), 4.18 (d, 1 H), 4.07 (d, 1 H), 3.96 (d, 1 H).19F-NMR (376 MHz, CDCI3): delta – 1 19.6 (s), (- 126.53) – (- 129.20) (dq).

1260670-05-0 is used more and more widely, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

Reference£º
Patent; NOVARTIS AG; HURTH, Konstanze; JACQUIER, Sebastien; MACHAUER, Rainer; RUEEGER, Heinrich; TINTELNOT-BLOMLEY, Marina; VEENSTRA, Siem Jacob; VOEGTLE, Markus; WO2013/54291; (2013); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

Brief introduction of 1260670-05-0

The synthetic route of 1260670-05-0 has been constantly updated, and we look forward to future research findings.

1260670-05-0, 3-Bromo-8-chloro-1,7-naphthyridine is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,1260670-05-0

A mixture of 3-bromo-8-chloro-1,7-naphthyridine (PharmaBlock catPBLJ2743: 0.200 g, 0.821 mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (Aldrich cat663348: 153 muL, 0.904 mmol), sodium carbonate (0.174 g, 1.64 mmol) and [1,1?-bis(dicyclohexylphosphino)ferrocene]dichloropalladium( II) (Aldrich cat701998: 6.2 mg, 0.0082 mmol) in tert-butyl alcohol (5.91 mL, 61.8 mmol) and water (6 mL, 300 mmol) was degassed and sealed. It was stirred at 110 C. for 2 h. The reaction mixture was cooled to room temperature then extracted with ethyl acetate (3¡Á20 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The crude residue was used directly in the next step without further purification. LC-MS calculated for C10H8ClN2 (M+H)+: m/z=191.0; found 191.0.

The synthetic route of 1260670-05-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Incyte Corporation; Wu, Liangxing; Qian, Ding-Quan; Lu, Liang; Lajkiewicz, Neil; Konkol, Leah C.; Li, Zhenwu; Zhang, Fenglei; Li, Jingwei; Wang, Haisheng; Xu, Meizhong; Xiao, Kaijiong; Yao, Wenqing; (101 pag.)US2018/177784; (2018); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

New learning discoveries about 1260670-05-0

With the rapid development of chemical substances, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

3-Bromo-8-chloro-1,7-naphthyridine, cas is 1260670-05-0, it is a common heterocyclic compound, the naphthyridine compound, its synthesis route is as follows.

General procedure: Parallel preparation of examples 6-7: To a set of vials containing the requisite aryl halide (0.20 mmol) was added a solution of HI (50 mg, 0.10 mmol) in THF (1.0 mL). The vials were capped and transferred into a glove box under an atmosphere of nitrogen. To each vial was then added a solution of LHMDS (1.0 M in THF, 0.25 mL, 0.25 mmol). The mixtures were then heated at 50 C with stirring overnight. After that time, water (2 mL) and DCM (2 mL) were added to each vial. The mixtures were transferred to a set of fritted barrel filters. The organic layer from each vial was drained into a clean vial. Additional DCM (1 mL) was added to each aqueous layer and the organic layer was again drained and combined with the previous organic extract. The solvent from the combined organic layers was removed in vacuo. To each vial was then added water (0.050 mL) and TFA (0.5 mL). The mixtures were stirred at 50C with stirring overnight. After that time, the mixtures were concentrated in vacuo. The crude residues were dissolved in DMSO (1 mL) and filtered. The crude residue containing Example 6 was purified by mass triggered preparative HPLC. [column: Waters XBridge CI 8, 5mupiiota , 19×100 mm; solvent: gradient 35-70% MeCN (0.1% NH4OH) in water (0.1% NH4OH) 25 mL/min; 8 min run time] to afford Example 6. The crude residue containing Example 7 was purified by mass triggered preparative HPLC [Waters Sunfire CI 8 column, 5muetaiota, 19 100 mm, using a gradient from 10% initial to 45% final MeCN (0.1% TFA) in water (0.1% TFA), 25 mL/min, 8 min run time] to afford Example 7., 1260670-05-0

With the rapid development of chemical substances, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

Reference£º
Patent; MERCK SHARP & DOHME CORP.; CUMMING, Jared, N.; SCOTT, Jack, D.; (65 pag.)WO2016/40226; (2016); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

The important role of 1260670-05-0

With the complex challenges of chemical substances, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

Name is 3-Bromo-8-chloro-1,7-naphthyridine, as a common heterocyclic compound, it belongs to naphthyridine compound, and cas is 1260670-05-0, its synthesis route is as follows.,1260670-05-0

Step 2 To a stirred solution of intermediate M-2 (90.0 mg, 0.20 mmol) and 3-bromo-8-chloro-l ,7- naphthyridine (74.0 mg, 0.30 mmol) in THF (3 mL) was added LHMDS (1 M in THF, 0.510 mL, 0.51 mmol) at RT and the mixture was heated at 45 C. After 2 h, additional 1 eq. of LHMDS was added and the mixture was stirred overnight at 45 C. The reaction was quenched with saturated NH4C1 and extracted with DCM. The combined organic extracts were dried over Na2S04 and concentrated. The resulting residue was treated with 5 mL of DCM and TFA (0.5 mL) was added. The mixture was stirred at 25 C for 2 h, then nuetralized with saturated NaHC03 and extracted with DCM. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by p-TLC (DCM: MeOH = 15 : 1) to afford compound M-3. MS for M-3: m/e = 551 and 553 (M+l).

With the complex challenges of chemical substances, we look forward to future research findings about 3-Bromo-8-chloro-1,7-naphthyridine

Reference£º
Patent; MERCK SHARP & DOHME CORP.; WALSH, Shawn, P.; CUMMING, Jared, N.; HE, Shuwen; TAOKA, Brandon, M.; TRUONG, Quang, T.; WU, Wen-Lian; (122 pag.)WO2015/187437; (2015); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

Brief introduction of 1260670-05-0

The synthetic route of 1260670-05-0 has been constantly updated, and we look forward to future research findings.

1260670-05-0, 3-Bromo-8-chloro-1,7-naphthyridine is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,1260670-05-0

Ammonium hydroxide (40 mL, 1.04 mol, 28%) was added to a solution of 3-bromo- 8-chloro-l,7-naphthyridine (1.00 g, 4.11 mmol) and THF (10 mL) in a sealed tube. The mixture was sealed, stirred at 100 C overnight, diluted with H20 (100 mL), and then extracted with EtOAc (3 x50 mL). The combined organic layers were washed (2x 100 mL brine), dried (Na2S04), filtered, and concentrated to dryness to give Intermediate 9 (824 mg, 89%) as a yellow solid. 1H NMR (400MHz, DMSO-i): delta 8.81 (s, 1H), 8.51 (s, 1H), 7.90 (d, 1H), 7.05 (br s, 2H), 6.87 (d, 1H); MS: 223.9 [M+H]+.

The synthetic route of 1260670-05-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; METACRINE, INC.; SMITH, Nicholas D.; GOVEK, Steven P.; NAGASAWA, Johnny Y.; (167 pag.)WO2018/170167; (2018); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

New learning discoveries about 1260670-05-0

As the paragraph descriping shows that 1260670-05-0 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1260670-05-0,3-Bromo-8-chloro-1,7-naphthyridine,as a common compound, the synthetic route is as follows.,1260670-05-0

Step 1 To a stirred solution of intermediate D-7 (200 mg, 0.45 mmol) and 3-bromo-8-chloro-l ,7- naphthyridine (165 mg, 0.68 mmol) in THF (8 mL) was added LHMDS (1 M in THF, 1.13 mL, 1.13 mmol) at RT. The mixture was stirred at 45 C for 2 h, then an additional 1 eq. of LHMDS was added and the mixture was stirred at 45 C overnight. The mixture was diluted with saturated Nu0 and extracted with DCM. The combined organic extracts were dried over Na2S04 and concentrated. The resulting residue was rediluted with 5 mL of DCM and TFA (0.5 mL) was added. The resulting mixture was stirred at 25 C for 2 h, then neutralized with NaHC03, and extracted with DCM. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by prep-TLC (DCM: MeOH = 15 : 1) to afford compound L-1. MS for L-1 : m/e = 550 and 552 (M+l).

As the paragraph descriping shows that 1260670-05-0 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; WALSH, Shawn, P.; CUMMING, Jared, N.; HE, Shuwen; TAOKA, Brandon, M.; TRUONG, Quang, T.; WU, Wen-Lian; (122 pag.)WO2015/187437; (2015); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

Downstream synthetic route of 1260670-05-0

As the paragraph descriping shows that 1260670-05-0 is playing an increasingly important role.

1260670-05-0, 3-Bromo-8-chloro-1,7-naphthyridine is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,1260670-05-0

Step 2 To a stirred solution of intermediate M-2 (90.0 mg, 0.20 mmol) and 3-bromo-8-chloro-l ,7- naphthyridine (74.0 mg, 0.30 mmol) in THF (3 mL) was added LHMDS (1 M in THF, 0.510 mL, 0.51 mmol) at RT and the mixture was heated at 45 C. After 2 h, additional 1 eq. of LHMDS was added and the mixture was stirred overnight at 45 C. The reaction was quenched with saturated NH4C1 and extracted with DCM. The combined organic extracts were dried over Na2S04 and concentrated. The resulting residue was treated with 5 mL of DCM and TFA (0.5 mL) was added. The mixture was stirred at 25 C for 2 h, then nuetralized with saturated NaHC03 and extracted with DCM. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by p-TLC (DCM: MeOH = 15 : 1) to afford compound M-3. MS for M-3: m/e = 551 and 553 (M+l).

As the paragraph descriping shows that 1260670-05-0 is playing an increasingly important role.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; WALSH, Shawn, P.; CUMMING, Jared, N.; HE, Shuwen; TAOKA, Brandon, M.; TRUONG, Quang, T.; WU, Wen-Lian; (122 pag.)WO2015/187437; (2015); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

Simple exploration of 1260670-05-0

1260670-05-0 3-Bromo-8-chloro-1,7-naphthyridine 72213592, anaphthyridine compound, is more and more widely used in various fields.

1260670-05-0, 3-Bromo-8-chloro-1,7-naphthyridine is a naphthyridine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Method N B-9 Ex. 3 To a stirred solution of Intermediate B-9 (400 mg, 0.937 mmol) and 3-bromo-8-chloro-l,7- naphthyridine (252 mg, 1.03 mmol) in THF (10 mL) was added LHMDS (1 M in THF, 3.28 mL, 3.28 mmol) at RT. The mixture was stirred at 45 C overnight, quenched with NH CI (sat.) and extracted with DCM. The combined organic extracts were dried over Na2S04 and concentrated. The residue was treated with 5 mL of DCM and 0.5 mL of TFA and stirred at 25 C for 2 h. The mixture was neutralized with NaHC03 and extracted with DCM. The organic layer was washed with brine, dried over Na2S04 and concentrated. The residue was purified by silica column chromatography (PE: EtOAc = 1 : 1) to afford example 3. MS for example 3: m/e = 533 and 535 (M+l)., 1260670-05-0

1260670-05-0 3-Bromo-8-chloro-1,7-naphthyridine 72213592, anaphthyridine compound, is more and more widely used in various fields.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; WALSH, Shawn, P.; CUMMING, Jared, N.; HE, Shuwen; TAOKA, Brandon, M.; TRUONG, Quang, T.; WU, Wen-Lian; (122 pag.)WO2015/187437; (2015); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem

Some tips on 1260670-05-0

1260670-05-0 3-Bromo-8-chloro-1,7-naphthyridine 72213592, anaphthyridine compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1260670-05-0,3-Bromo-8-chloro-1,7-naphthyridine,as a common compound, the synthetic route is as follows.,1260670-05-0

To a solution of 3-bromo-8-chloro-1, 7-naphthyridine (2.43g) in toluene (30mL) , EtOH (10mL) , and 10%Na2CO3aq. (10mL) Pd (dppf) Cl2.DCM (420mg) was added. 4, 4, 5, 5-tetramethyl-2-vinyl-1, 3, 2-dioxaborolane (3.1g) was added dropwise under N2protection. The mixture was allowed to stir at 100 for 16 h. The reaction was quenched by H2O (50mL) and extracted by EtOAc for 3 times. Organic layer was combined and washed with brine. The resulting solution was concentrated and purified by silicagel (eluting with hexane-EtOAc using a gradient from 8: 1 to 5: 1) to afford 8-chloro-3-vinyl-1, 7-naphthyridine (1.1g) as a brown solid.

1260670-05-0 3-Bromo-8-chloro-1,7-naphthyridine 72213592, anaphthyridine compound, is more and more widely used in various fields.

Reference£º
Patent; BETTA PHARMACEUTICALS CO., LTD; WANG, Yiqian; FU, Bang; ZHANG, Yao; LIU, Xiangyong; WANG, Jiabing; DING, Lieming; (103 pag.)WO2019/192506; (2019); A1;,
1,8-Naphthyridine – Wikipedia
1,8-Naphthyridine | C8H6N2 – PubChem